DIRS.INFO The most relevant business & tech news

☆ Novartis lifts guidance after first-quarter results beat expectations
▼ + stars: | 2024-04-23 | by ( ) www.cnbc.com time to read: +2 min

Signage is displayed on the exterior of the Novartis AG Institutes for BioMedical Research building in Cambridge, Massachusetts, U.S., on Friday, Aug. 5, 2016. Swiss drugmaker Novartis on Tuesday raised its full-year guidance after reporting better-than-expected first-quarter results. In a statement, it said 2024 net sales would likely grow by a high-single to low double-digit percentage with adjusted operating income expected to grow by a low double-digit to mid-teens percentage. It has previously predicted that adjusted operating income would increase by a "high single-digit" percentage with "mid single-digit" sales growth. Quarterly adjusted operating income gained 16% to $4.54 billion, beating an average analyst estimate of about $4.3 billion.

Persons: Bristol Myers, Giovanni Caforio, Joerg Reinhardt, Vas Narasimhan, Sandoz Organizations: Novartis, Institutes, Research, Bristol, Bristol Myers Squibb Locations: Cambridge , Massachusetts, U.S

☆ Novartis misses Q4 net income expectations, extends forecast
▼ + stars: | 2024-01-31 | by ( ) www.cnbc.com time to read: 1 min

Novartis said in August that it plans to spin off its generics unit Sandoz to sharpen its focus on its patented prescription medicines. Swiss drugmaker Novartis reported a 6% gain in fourth-quarter adjusted net income on Wednesday, helped by cost cuts and strong growth of recently launched drugs. Core net income for the quarter came in at $3.13 billion, it said in a statement, missing analysts' estimate of about $3.3 billion, as per LSEG data. Novartis also extended its mid-term guidance, saying it expected sales to grow 5% per year until 2028, when adjusting for currency swings. CEO Vas Narasimhan previously led a push to cut jobs and focus on fewer therapeutic areas and geographic markets, before spinning off and listing generic drugs business Sandoz late last year.

Persons: Sandoz, Vas Narasimhan Organizations: Novartis

☆ Morgan Stanley likes biopharma as a defensive play — giving one stock 119% upside
▼ + stars: | 2024-01-22 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

The biopharmaceutical sector is expected to offer a safe haven from macroeconomic and earnings concerns ahead of final quarterly results from companies, according to Morgan Stanley. Morgan Stanley, however, cautioned that the outlook for drug pricing reform in the U.S. poses risks for the sector. Shares of Indivior , argenx , AstraZeneca , Merck , Lonza, Sweden's Sobi, Novo Nordisk and Sandoz Group were among those listed by Morgan Stanley with a "buy" rating. In a bull case where Sublocade hits $2.2 billion in sales by 2030, Morgan Stanley sees shares rising further to 3,500 British pence. Novo Nordisk Shares of Novo Nordisk , a leader in diabetes and obesity drugs, offer a 9.4% upside, according to Morgan Stanley.

Persons: Morgan Stanley, Mark D Purcell, Sweden's, Sublocade, Thibault Boutherin, Morgan, — CNBC's Michael Bloom Organizations: Barclays, Bank of America, AstraZeneca, Merck, Lonza, Novo Nordisk, Sandoz Group, AstraZeneca AstraZeneca, British pharma, EU Locations: U.S, argenx, Novo, Indivior

☆ Missed the Novo and Lilly rally? These 4 under-the-radar anti-obesity drug stocks could soar, Berenberg says – giving one 44% upside
▼ + stars: | 2024-01-22 | by ( Ganesh Rao | ) www.cnbc.com time to read: +2 min

The anti-obesity drug market is expected to remain in focus this year after a bumper 2023 for weight loss drugmakers Novo Nordisk and Eli Lilly , according to Berenberg. GLP-1 drugs encourage the production of hormones that cause weight loss through reduced appetite. Nevertheless, Berenberg's analysts believe the bigger, underappreciated, near-term opportunity lies with companies preparing to launch generic versions of the first-generation GLP-1 drugs. Under-the-radar picks Sartorius and SKAN Group, Berenberg's "under-the-radar" pick, are also expected to benefit from manufacturing generic GLP-1 drugs. The investment bank sees Sartorius benefiting from the growing commercialization of GLP-1 drugs and forecasts shares to rise by 27% over the next 12 months.

Persons: Eli Lilly, Novo, Sandoz, Berenberg Organizations: Novo Nordisk, —, Nordisk, Novo Nordisk's Victoza, SKAN Locations: Germany, Europe, Sandoz, United States

☆ 4 stock ideas I brought back from the JPMorgan Healthcare Conference and everything else I learned about the industry
▼ + stars: | 2024-01-15 | by ( Jim Cramer | ) www.cnbc.com time to read: +12 min

We will go over them – but first, let me talk about what I learned at last week's JPMorgan Health Care Conference that I attended in San Francisco, and what it means to your portfolio. We know health care has a lot of angles too it. The previous CEO Roz Brewer was from Starbucks and struggled with the role that Walgreens plays in health care. You have to be following the transformation of Bristol-Myers, which is opening its wallet to buy a host of drug companies, including anti-psychotic firm Karuna. Health care is the way to go.

Persons: Regeneron, Pfizer, Eli Lilly, Dave Ricks, Lilly, donanemab, Lilly's, Zepbound, it's, Abbott, It's, Roche, Merck, Myers, ABT, Robert Ford, Tim Wentworth, He's, Roz Brewer, Wentworth, he'll, Brewer wasn't, Bob Bradway, Amgen, Vas Narasimhan, Sandoz, Karuna, Medtronic, Hugo, Morgan Stanley, Wells, Covid, Cramer's, Jim Cramer, Jim, Las Vegas Brendan Smialowski Organizations: Abbott Labs, Covid, Novartis, Amgen, Walgreens Boots Alliance, JPMorgan Health Care Conference, Humana, Drug Administration, Novo Nordisk, Dickinson Co, Bristol, Myers Squibb, Pfizer, Department, WBA, Walgreens, Starbucks, -, pharma, Merck, Keytruda, Horizon Therapeutics, Federal Trade Commission, Myers, BD, CVS Health, JPMorgan, Cramer's Charitable, CNBC, Consumer, AFP, Getty Locations: San Francisco, GLP, North Carolina, Europe, Cencora, Amgen, West, Bristol, Target, Las Vegas

☆ Novartis lifts sales growth target to 5% per year through 2027
▼ + stars: | 2023-11-28 | by ( Ludwig Burger | ) www.reuters.com time to read: +1 min

The logo of Swiss drugmaker Novartis is pictured at the company's French headquarters in Rueil-Malmaison near Paris, France, April 22, 2020. REUTERS/Charles Platiau/File Photo Acquire Licensing RightsCompanies Novartis AG FollowSandoz GmbH FollowFRANKFURT, Nov 28 (Reuters) - Novartis (NOVN.S) has dialled up its sales growth target to 5% per year until 2027, citing demand for innovative drugs after it sold off its generic-drugs business. The medium-term target, which excludes any foreign exchange effects, is mainly driven by six drugs, led by Kisqali, it said in a presentation on Tuesday. The sales forecast, up from a previous revenue growth target of 4% through 2027, is also underpinned by demand for Pluvicto, a precision radiotherapy against prostate cancer, and self-administered multiple sclerosis (MS) shot Kesimpta. Reporting by Ludwig Burger; Editing by Miranda Murray and Miral FahmyOur Standards: The Thomson Reuters Trust Principles.

Persons: Charles Platiau, Kisqali, Vas, Kesimpta, drugmaker, Sandoz, Ludwig Burger, Miranda Murray, Miral Organizations: Swiss, Novartis, REUTERS, Companies Novartis, Sandoz, FRANKFURT, Thomson Locations: Rueil, Malmaison, Paris, France, Basel, Swiss

The logo for AbbVie is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, New York, U.S., November 17, 2021. Morningstar analyst Damien Conover said he had already factored in a hit to Imbruvica from the Medicare price negotiations, so the update on impairment was not "overly significant to our view." Humira's global third-quarter sales fell 36% to $3.55 billion, but topped analysts' estimates of $3.48 billion, according to LSEG data. AbbVie in July trimmed its 2023 view for Humira sales erosion to 35%, from 37% earlier. The company's newer immunology drugs Skyrizi and Rinvoq generated sales of $2.13 billion and $1.11 billion, respectively, ahead of analyst expectations of $2.10 billion and $1.02 billion.

Persons: Andrew Kelly, girding, AbbVie, Imbruvica, Morningstar, Damien Conover, Humira, Piper Sandler, Christopher Raymond, Ingelheim, Leroy Leo, Christy Santhosh, Maju Samuel, Bill Berkrot Organizations: New York Stock Exchange, REUTERS, U.S, Medicare, Analysts, Sandoz, AbbVie, Thomson Locations: New York City , New York, U.S, The Illinois, Bengaluru

☆ German voters send ominous message to Brussels
▼ + stars: | 2023-10-09 | by ( ) www.reuters.com time to read: +2 min

LONDON, Oct 9 (Reuters Breakingviews) - German Chancellor Olaf Scholz’s resounding defeat in key local elections on Sunday will be as traumatic in Brussels as in Berlin. Voters dealt a sharp blow to all three parties in Scholz’s centre-left executive. The victory of conservative opposition party CDU came together with a strong showing of far-right Alternative für Deutschland (AfD), who won 15% of the votes in the populous state of Bavaria and 18% in Hesse. In Berlin, divisions on the pace and cost of the green transition between the Green Party and the liberal FDP, whose leader Christian Lindner is the coalition’s finance minister, have already led to a watering down of a planned boiler ban from 2024. In Brussels, a German government preoccupied with its domestic travails may be unable to rally other member states around the sort of compromise proposals the EU needs to clinch some key deals.

Persons: Olaf Scholz’s, Christian Lindner, Scholz, Pierre Briancon, Sandoz, Lisa Jucca, Oliver Taslic Organizations: Reuters, Voters, Social Democrats, Greens, European Union, Green Party, X, Alstom, Brookfield, Thomson Locations: Brussels, Berlin, Scholz’s, Bavaria, Hesse, Germany, France, EU

☆ Schaeffler auto deal has multiple value drivers
▼ + stars: | 2023-10-09 | by ( ) www.reuters.com time to read: +2 min

The German share price index DAX graph is pictured at the stock exchange during the vitesco IPO in Frankfurt, Germany, September 16, 2021. REUTERS/Staff Acquire Licensing RightsLONDON, Oct 9 (Reuters Breakingviews) - Gearing up to take over an auto company on the eve of a recession might look risky. The merger will be done through a tender for the 50% of Vitesco’s stock not held by the family, then a merger with what's left. Cost synergies on top could be worth 3.5 billion euros in present value terms. As part of the merger, Schaeffler will adopt a more shareholder-friendly structure with equal voting rights.

Persons: what's, Schaeffler, Neil Unmack, Sandoz, George Hay, Streisand Neto Organizations: REUTERS, Staff, Reuters, Vitesco Technologies, X, Alstom, Thomson Locations: Frankfurt, Germany, China, Brussels

☆ Finnair is one daunting rights issue that can fly
▼ + stars: | 2023-10-06 | by ( ) www.reuters.com time to read: +2 min

A Finnair Airbus A320-200 aircraft prepares to take off from Manchester Airport in Manchester, Britain September 4, 2018. REUTERS/Phil Noble/File Photo Acquire Licensing RightsLONDON, Oct 6 (Reuters Breakingviews) - Rights issues worth almost the value of a company’s equity rarely get off the ground. Tell that to 700 million euro Finnair (FIA1S.HE), which on Friday unveiled a 600 million euro rights issue. For one thing, the Finnish state owns over half of the Nordic airline and is supporting the rights issue. The government is offsetting the cost of the cash call by being partly refunded a 400 million euro capital loan it granted to the airline in the wake of the pandemic.

Persons: Phil Noble, Aimee Donnellan, Tesla, Sandoz, George Hay, Oliver Taslic Organizations: Airbus, Manchester Airport, REUTERS, Reuters, Nordic, SAS, X, Alstom, Brookfield, Thomson Locations: Manchester, Britain

☆ Vietnam’s Tesla justifies stock price reversal
▼ + stars: | 2023-10-06 | by ( ) www.reuters.com time to read: +2 min

A VinFast VF 8 model is seen during a car delivery ceremony at the VinFast car factory in Haiphong province, Vietnam, September 10, 2022. REUTERS/Thinh Nguyen Acquire Licensing RightsSINGAPORE, Oct 6 (Reuters Breakingviews) - Vietnam’s richest man may have to get used to spending some time in the slow lane. In August, Pham Nhat Vuong closed an unconvincing merger with a blank-cheque company that bestowed a $23 billion market value on his Tesla (TSLA.O) wannabe VinFast . There are no details of sales in the United States, a key target market where it has been burdened by poor reviews. Without some impressive progress outside of Vietnam, though, the EV company’s stock is going nowhere fast.

Persons: Thinh Nguyen, Pham Nhat Vuong, Sandoz, Antony Currie, Thomas Shum Organizations: REUTERS, Rights, Reuters, EV, X, Alstom, Brookfield, Temasek, Thomson Locations: Haiphong province, Vietnam, Rights SINGAPORE, United States

☆ Alstom cash crunch dents management credibility
▼ + stars: | 2023-10-05 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Gonzalo Fuentes Acquire Licensing RightsLONDON, Oct 5 (Reuters Breakingviews) - Alstom (ALSO.PA) CEO Henri Poupart-Lafarge faces an uphill struggle to shore up his credibility. The French train maker lost 35% of its market value – amounting to 3 billion euros - on Thursday after announcing that it would book negative free cash flow of 500 to 750 million euros this year. Finally, weaker than expected orders in the first half of the year generated less cash in the form of down payments. Given the potential for the group’s net debt to be 3 billion euros by year-end, 1 billion euros more than expected, Deutsche Bank analysts reckon it may soon need a capital increase. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

Persons: Gonzalo Fuentes, Henri Poupart, Pierre Briancon, Aimee Donnellan, Streisand Neto Organizations: Alstom, REUTERS, Reuters, London Underground, Deutsche Bank, X, Sandoz, Brookfield, Temasek, Thomson Locations: Saint, Ouen, Paris, France

☆ Novartis unit Sandoz starts trading at 24 Swiss francs after completing spinoff
▼ + stars: | 2023-10-04 | by ( Elliot Smith | ) www.cnbc.com time to read: +1 min

Novartis said in August that it plans to spin off its generics unit Sandoz to sharpen its focus on its patented prescription medicines. Novartis on Wednesday completed the spinoff of its generics and biosimilars business Sandoz, whose shares began trading at 24 Swiss francs in the early minutes of the company's debut on the SIX Swiss Exchange. The Swiss drugmaker initially announced intentions to spin off the business in August, offering stakeholders one Sandoz share for every five Novartis shares via a dividend-in-kind distribution. Pure play companies refer to entities that target a single product or industry sector. Novartis shares climbed more than 3% in early trade in Zurich to lead the pan-European Stoxx 600 index .

Persons: Sandoz, Narasimhan, we've, CNBC's Julianna Tatelbaum Organizations: Novartis, Wednesday, SIX Swiss Exchange, CNBC Locations: Swiss, Zurich

☆ Stocks making the biggest moves premarket: Cal-Maine Foods, Intel, Apple & more
▼ + stars: | 2023-10-04 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Intel — Shares popped 2.5% after the chipmaker announced it would be operating its programmable chip unit as a standalone business complete. Intel plans to conduct an initial public offering for the unit within the next two to three years. The firm is bullish on the stock thanks to progress on legacy projects and said Fluor is on the brink of a company turning point. Sunrun , Sunnova Energy International — Shares of Sunrun and Sunnova dropped 3% and 2.8%, respectively, after Truist Securities downgraded the solar panel installers to hold from buy on Wednesday. Cal-Maine Foods — The stock plunged 11.6% after the company came out with disappointing sales figures due to lower prices.

Persons: Fluor, Sunnova, Moderna, StreetAccount, — CNBC's Brian Evans, Lisa Han Organizations: Intel, UBS, Apple, Sunnova Energy, Truist Securities, Moderna, pharma, Bank of America, Novartis —, Swiss drugmaker, Sandoz, SIX Swiss Exchange, Maine Foods, Revenue Locations: United States, Israel, Swiss, Cal

☆ 'Regulators are seeing the importance' of generic drugs, Sandoz CEO says
▼ + stars: | 2023-10-04 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via Email'Regulators are seeing the importance' of generic drugs, Sandoz CEO saysSandoz CEO Richard Saynor speaks with CNBC after the completion of its spinoff from parent company Novartis.

Persons: Sandoz, Richard Saynor Organizations: Email, CNBC, Novartis

☆ Novartis' Sandoz valued at $11.2 bln in market debut
▼ + stars: | 2023-10-04 | by ( ) www.reuters.com time to read: +1 min

A sign marks the Novartis Institutes for BioMedical Research facility in Cambridge, Massachusetts, U.S., June 16, 2021. REUTERS/Brian Snyder/File Photo Acquire Licensing RightsOct 4 (Reuters) - Sandoz (SDZ.S) made its market debut with a lower-than-expected valuation of 10.3 billion Swiss francs ($11.2 billion) on Wednesday, after the generic and biosimilar drugmaker was spun off from Swiss pharmaceutical company Novartis (NOVN.S). Deutsche Bank had said Sandoz, which accounted for 11% of Novartis' group operating profit in 2022, would likely be valued at $11-$13 billion, while brokerage Berenberg had forecast $17-$26 billion. The shares, which opened at 24 Swiss francs, became members of the Swiss Performance Index and the Swiss Leader Index, among other stock market gauges, and American depositary receipts also started trading on Wednesday. Novartis shareholders received one Sandoz share for every five Novartis shares they held as part of the transaction.

Persons: Brian Snyder, drugmaker, Sandoz, Berenberg, Vas Narasimhan, Ludwig Burger, Tristan Veyet, Clarence Fernandez, Mark Potter Organizations: Novartis, Research, REUTERS, Sandoz, Analysts, Deutsche Bank, Swiss, Thomson Locations: Cambridge , Massachusetts, U.S, Swiss, generics

☆ Novartis CEO: Spinoffs will see us succeed as a pure-play innovative medicines company
▼ + stars: | 2023-10-04 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovartis CEO: Spinoffs will see us succeed as a pure-play innovative medicines companyNovartis CEO Vas Narasimhan discusses what the spinoff of the company's Sandoz unit means for the organization.

Persons: Vas, Sandoz Organizations: Novartis

☆ Sandoz owners are banking on margin cure
▼ + stars: | 2023-10-04 | by ( ) www.reuters.com time to read: +2 min

LONDON, Oct 4 (Reuters Breakingviews) - Sandoz’s (SDZ.S) investors are giving CEO Richard Saynor the benefit of the doubt. Shares in the generics drug maker, which $217 billion pharma giant Novartis (NOVN.S) has finally managed to spin off, started to trade in Zurich on Wednesday. There was a risk that Novartis investors, who have long called for a sale or spinoff, would quickly dump the new Sandoz shares. At current market prices, Sandoz is worth nearly $11 billion, or $14.4 billion once net debt is added in. For now, Novartis investors seem to believe Sandoz’s treatment may be effective.

Persons: Richard Saynor, Sandoz, Aimee Donnellan, Lisa Jucca, Streisand Neto Organizations: Reuters, Novartis, Sandoz, Hikma Pharmaceuticals, X, Brookfield pounces, Temasek, Thomson Locations: Zurich, That’s

☆ Novartis positioning is now best-suited for long-term gains and returns after spin-off, says CEO
▼ + stars: | 2023-10-03 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovartis positioning is now best-suited for long-term gains and returns after spin-off, says CEONovartis CEO Vas Narasimhan joins 'Squawk on the Street' to discuss the company's new spin-off Sandoz, what a pure-play core pharmaceutical company means, and the idea of M&A to boost the company's growth prospects.

Persons: Vas Narasimhan, Sandoz Organizations: Novartis

☆ Watch CNBC's full interview with Novartis CEO Vas Narasimhan
▼ + stars: | 2023-10-03 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWatch CNBC's full interview with Novartis CEO Vas NarasimhanNovartis CEO Vas Narasimhan joins 'Squawk on the Street' to discuss the company's new spin-off Sandoz, what a pure-play core pharmaceutical company means, and the idea of M&A to boost the company's growth prospects.

Persons: Vas Narasimhan, Sandoz Organizations: Novartis

☆ Novartis CEO: Company set to become a pure play, innovative medicine business after Sandoz spin off
▼ + stars: | 2023-10-03 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovartis CEO: Company set to become a pure play, innovative medicine business after Sandoz spin offVas Narasimhan, CEO at Novartis, discusses the company's 100% spin off of Sandoz, its generic and biosimilar medicines business, and what the deal means for shareholders.

Organizations: Novartis, Sandoz Locations: Sandoz

☆ Novartis confirms Sandoz spin-off for October 4, 2023
▼ + stars: | 2023-09-25 | by ( ) www.reuters.com time to read: 1 min

The company's logo is seen at the cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann/File Photo Acquire Licensing RightsCompanies Novartis AG FollowZURICH, Sept 25 (Reuters) - Novartis (NOVN.S) on Monday confirmed its plans for a 100% spin-off of the Sandoz business on Oct. 4 after shareholders gave their approval earlier this month. Novartis also said key regulatory approvals have been obtained, including the approval by SIX Exchange Regulation for the listing of the Sandoz shares on the SIX Swiss Exchange. The Sandoz shares will have the symbol SDZ, Novartis said. Reporting by John Revill, Editing by Rachel MoreOur Standards: The Thomson Reuters Trust Principles.

Persons: Arnd, Sandoz, John Revill, Rachel More Organizations: Novartis, REUTERS, Companies Novartis, SIX, Sandoz, SIX Swiss Exchange, Thomson Locations: Swiss, Stein, Switzerland

☆ Amoxicillin shortage: A new season of infections is here, but the shortage of a common kids’ antibiotic never ended
▼ + stars: | 2023-09-22 | by ( Brenda Goodman | ) edition.cnn.com time to read: +7 min

Respiratory illness season is coming up, and that’s going to be a huge issue,” said David Margraf, a pharmaceutical research scientist with the University of Minnesota’s Resilient Drug Supply Project. During a drug shortage, allocation helps ensure that no single buyer can claim all the available supply. Khazanchi and his colleague Dr. Ryan Brewster recently studied the clinical effects of last winter’s amoxicillin shortage. “Drug shortages will likely continue to increase if the pricing dynamics in the marketplace are not addressed,” Sandoz said in a statement. “The companies refuse to tell us what’s going on,” said Erin Fox, who tracks drug shortages at the University of Utah.

Persons: —, earaches, ”, David Margraf, Selena Ko, Erin Hooley, pediatricians, Rohan Khazanchi, Khazanchi, Ryan Brewster, Amoxicillin, ” Khazanchi, “ It’s, ” Sandoz, Erin Fox, Laura Bray, They’re, ” Margraf, ” Bray, Dr, Sanjay Gupta, “, Matt Christian Organizations: CNN, Food, University of, Project, Rush University Medical Center, Chicago Tribune, TNS, Getty, FDA, Brigham & Women’s Hospital, Teva Pharmaceuticals, Novartis, University of Utah, Angels, CNN Health, US Department of Agriculture, Pharmacopeia’s Medicines Locations: Chicago, Boston

☆ The ADHD drug market is already stretched thin. Now it's facing a back-to-school supply strain
▼ + stars: | 2023-08-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +8 min

Ten milligram tablets of the hyperactivity drug, Adderall, made by Shire Plc. Adderall and alternative ADHD medications apart from other drugs are Schedule 2 controlled substances. Production limitationsEnding the shortages of Adderall and other ADHD medications is no easy task. That means increasing the production of one drug could potentially require reducing production — and potentially impacting supply — of another drug, according to Ergun. That includes Aytu BioPharma, which makes an ADHD drug that used to be in shortage.

Persons: Jb Reed, It's, Erin Fox, they've, David Margraf, Margraf, drugmakers, Ozlem Ergun, Ergun, Novartis's, Michael Ganio, ASHP's Ganio, RJ Sangosti, Josh Disbrow, Fox Organizations: Shire Plc, Jb, Bloomberg, Getty, and Drug Administration, CNBC, University of Utah, American Society of Health, System Pharmacists, Centers for Disease Control, University of Minnesota's, Infectious Disease, Northeastern University, Teva Pharmaceuticals, Amneal Pharmaceuticals, Sandoz, Purdue Pharma, Rhodes Pharmaceuticals, Drug, Fox, Pharmacists, Drug Enforcement Administration, MediaNews, Denver, FDA, DEA Locations: U.S, Commerce City , Colorado

☆ CVS pushes into making cheaper versions of complex drugs with new discount Humira
▼ + stars: | 2023-08-23 | by ( Bertha Coombs | ) www.cnbc.com time to read: +4 min

CVS Health is partnering with drugmaker Sandoz to produce a near identical version of the blockbuster arthritis treatment Humira that will sell for 80% below the price of the brand-named drug. The move is part of the company's new venture focused on securing, and in some cases co-producing, biosimilar drugs, which are the equivalent of generic versions of complex gene or protein-based therapies known as biologics. CVS is already one of the leading players when it comes to sourcing generic drugs through Red Oak, its joint venture with Cardinal Health . Abbvie reported more than $4 billion in Humira sales in its most recent quarter, which was slightly better than expected. Correction: CVS Health subsidiary Cordavis will partner with Sandoz on biosimilar drugs.

Persons: drugmaker Sandoz, We've, it'll, Prem Shah, drugmaker, Amgen's Amjevita, Murdo Gordon, Abbvie, Cuban's, John Ransom, Raymond James, Ransom, Sandoz Organizations: CVS Health, CVS, Cardinal Health, Novartis Pharmaceuticals, Sandoz, Novartis, FDA, Blue, Drug Company, Amazon Pharmacy Locations: U.S, Red, California

Search resuls for: "Sandoz"

25 mentions found